- Conditions
- Endometriosis
- Interventions
- Placebo, OBE2109
- Drug
- Lead sponsor
- ObsEva SA
- Industry
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 328 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 71
- States / cities
- Chandler, Arizona • Scottsdale, Arizona • Arcadia, California + 59 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–9
of 9
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Endometriosis
- Interventions
- 75 mg linzagolix tablet, 200 mg linzagolix tablet, Add-back capsule (E2 1 mg / NETA 0.5 mg), Placebo tablet to match 75 mg linzagolix tablet, Placebo tablet to match 200 mg linzagolix tablet, Placebo capsule to match Add-back capsule
- Drug
- Lead sponsor
- Kissei Pharmaceutical Co., Ltd.
- Industry
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 23
- States / cities
- Little Rock, Arkansas • Norwalk, California • Greenwood Village, Colorado + 17 more
- Conditions
- Endometriosis
- Interventions
- 75 mg linzagolix tablet, 200 mg linzagolix tablet, Add-back capsule (E2 1 mg / NETA 0.5 mg), Placebo tablet to match 75 mg linzagolix tablet, Placebo tablet to match 200 mg linzagolix tablet, Placebo capsule to match Add-back capsule
- Drug
- Lead sponsor
- Kissei Pharmaceutical Co., Ltd.
- Industry
- Eligibility
- 18 Years to 49 Years · Female only
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 107
- States / cities
- Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 79 more
- Conditions
- Uterine Fibroids, Heavy Menstrual Bleeding
- Interventions
- OBE2109, Placebo to match OBE2109, Placebo to match Add-back, Add-back
- Drug
- Lead sponsor
- ObsEva SA
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 526 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 116
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 93 more
- Conditions
- Uterine Fibroids, Heavy Menstrual Bleeding
- Interventions
- OBE2109, Placebo to match OBE2109, Placebo to match Add-back, Add-back
- Drug
- Lead sponsor
- ObsEva SA
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 511 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 23
- States / cities
- Chino, California • Huntington Park, California • San Diego, California + 19 more
- Conditions
- Endometriosis
- Interventions
- 75 mg linzagolix tablet, 200 mg linzagolix tablet, Add-back capsule (E2 1 mg / NETA 0.5 mg), Placebo tablet to match 75 mg linzagolix tablet, Placebo tablet to match 200 mg linzagolix tablet, Placebo capsule to match Add-back capsule
- Drug
- Lead sponsor
- Kissei Pharmaceutical Co., Ltd.
- Industry
- Eligibility
- 18 Years to 49 Years · Female only
- Enrollment
- 486 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Chiefland, Florida + 19 more
- Conditions
- Renal Impairment, Healthy Participants
- Interventions
- Linzagolix
- Drug
- Lead sponsor
- ObsEva SA
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 33 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 2
- States / cities
- Orlando, Florida • Saint Paul, Minnesota
- Conditions
- Endometriosis
- Interventions
- 75 mg linzagolix tablet, 200 mg linzagolix tablet, Placebo tablet to match 75 mg linzagolix tablet, Placebo tablet to match 200 mg linzagolix tablet, Add-back capsule (E2 1 mg / NETA 0.5 mg), Placebo capsule to match Add-back capsule
- Drug
- Lead sponsor
- Kissei Pharmaceutical Co., Ltd.
- Industry
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 356 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 8
- States / cities
- Dothan, Alabama • Homestead, Florida • Tampa, Florida + 5 more
- Conditions
- Hepatic Impairment, Healthy Participants
- Interventions
- Linzagolix
- Drug
- Lead sponsor
- ObsEva SA
- Industry
- Eligibility
- 18 Years to 75 Years · Female only
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019
- U.S. locations
- 2
- States / cities
- Hialeah, Florida • Orlando, Florida